Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting

Circulation Journal

Volumn 69, Issue 12, 2005, Pages 1477-1483

  Young, Joon Hong ^a   Myung, Ho Jeong ^a,b   Sang, Yup Lim ^a   Sang, Rok Lee ^a   Kye, Hun Kim ^a   Il, Suk Sohn ^a   Hyung, Wook Park ^a   Ju, Han Kim ^a   Kim, Weon ^a   Ahn, Youngkeun ^a   Jeong, Gwan Cho ^a   Jong, Chun Park ^a   Jung, Chaee Kang ^a  

^a Chonnam National University Medical School   (South Korea)

^b Department of Cardiovascular Medicine ^*  (South Korea)

Author keywords

Inflammation; Restenosis; Stent

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; RISK ASSESSMENT;

ADULT; AGED; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY VESSELS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERPLASIA; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; STENTS; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 28544435747     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1477     Document Type: Article

References (43)

1. Choi H, Cho DH, Shin HH, Park JB. Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension. Circ J 2004; 68: 297 - 303.
2. Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: The Minoh Study. Circ J 2005; 69: 386 - 391.
3. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007 - 2011.
4. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499 - 511.
5. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557 - 1565.
6. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959 - 1965.
7. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383 - 1389.
8. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349 - 1357.
9. The Heart Protection Study Collaborative Group. The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo controlled trial. Lancet 2002; 360: 7-22.
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001 - 1009.
11. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications: Part 2. Clin Chem 2001; 47: 418 - 425.
12. Walter DH, Schachinger V, Elsner M, Di mmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphism and risk of coronary stent thrombosis. Lancet 1997; 350: 1217 - 1219.
13. Nissen SE, Yock P. Intravascular ultrasound: Novel pathophysiological insights and current clinical applications. Circulation 2001; 103: 604 - 616.
14. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994; 331: 489 - 495.
15. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496 - 501.
16. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003; 107: 381 - 383.
17. Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: A serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003; 107: 517 - 520.
18. Hong YJ, Jeong MH, Kim W, Lim SY, Lee SH, Hong SN, et al. Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. Am J Cardiol 2004; 94: 1050 - 1054.
19. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study. Circulation 1996; 94: 1247 - 1254.
20. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen. J Am Coll Cardiol 2000; 35: 157 - 163.
21. Li C, Cantor WJ, Nili N, Robinson R, Fenkell L, Tran YL, et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol 2002; 39: 1852 - 1858.
22. Bellas RE, Lee JS, Sonenshein GE. Expression of a constrictive NF-• B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 1995; 96: 2521 - 2527.
23. Welt FGP, Rogers C. Infla mmation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22: 1769 - 1776.
24. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, et al. Enhanced infla mmatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98: 2370 - 2376.
25. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. Instent restenosis: Contributions of infla mmatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224 - 230.
26. Lim SY, Jeong MH, Bae EH, Kim W, Kim JH, Hong YJ, et al. Predictive factors of major adverse cardiac events in acute myocardial infarction patients complicated by cardiogenic shock undergoing primary percutaneous coronary intervention. Circ J 2005; 69: 154 - 158.
27. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512 - 1521.
28. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis after Stent Implantation Study. J Am Coll Cardiol 2002; 40: 1375 - 1382.
29. Kawamoto R, Hatakeyama K, Imamura T, Ishikawa T, Date H, Shibata Y, et al. Relation of C-reactive protein to restenosis after coronary stent implantation and to restenosis after coronary atherectomy. Am J Cardiol 2004; 94: 104 - 107.
30. Angioi M, Abdelmouttaleb I, Rodriguez RM, Aimone-Gastin I, Adjalla C, Gueant JL, et al. Increased C-reactive protein levels in patients with in-stent restenosis and its complications. Am J Cardiol 2001; 87: 1189 - 1193.
31. Hong YJ, Jeong MH, Park OY, Kim W, Kim JH, Ahn YK, et al. The role of C-reactive protein in patients with acute myocardial infarction after primary or rescue percutaneous coronary intervention. Korean J Intern Med 2003; 18: 29 - 34.
32. Nishioka T, Luo H, Eigler NL, Berglund H, Kim CJ, Siegel RJ. Contribution of inadequate compensatory enlargement to development of human coronary artery stenosis: An in vivo intravascular ultrasound study. J Am Coll Cardiol 1996; 27: 1571 - 1576.
33. Hong YJ, Jeong MH, Hyun DW, Hur SH, Kim KB, Kim W, et al. Impact of preinterventional arterial remodeling on in-stent neointimal hyperplasia and in-stent restenosis after coronary stent implantation. Circ J 2005; 69: 414 - 419.
34. Okimoto T, Imazu M, Hayashi Y, Fujiwara H, Ueda H, Kohno N. Atherosclerotic plaque characterization by quantitative analysis using intravascular ultrasound: Correlation with histological and immunohistochemical findings. Circ J 2002; 66: 173 - 177.
35. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118 - 119.
36. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal infla mmation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057 - 2064.
37. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227 - 3233.
38. Lacoste L, Lam JY, Hung J. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172 - 3177.
39. Lefer DJ. Statins as potent anti-infla mmatory drugs. Circulation 2002; 106: 2041 - 2042.
40. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983 - 984.
41. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin and plasma concentration of C-reactive protein. Circulation 1999; 100: 230 - 235.
42. Mulder HJ, Bal ET, Jukema JW, Zwinderman AH, Schalij MJ, van Boven AJ, et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol 2000; 86: 742 - 746.
43. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000; 85: 962 - 968.